The first drug of a new antibiotic class has been approved for urinary tract infections and gonorrhoea, offering a fresh weapon against drug-resistant bacteria. Gepotidacin, sold as Blujepa by GSK, is a first-in-class triazaacenaphthylene antibiotic that blocks two bacterial enzymes, DNA gyrase and topoisomerase IV, which bacteria need to copy their DNA. The US Food and Drug Administration approved it for uncomplicated urinary tract infections in females aged 12 and over who weigh at least 40 kilograms, and in December 2025 for uncomplicated urogenital gonorrhoea in patients aged 12 and over weighing at least 45 kilograms who have limited or no alternative treatments. It is also approved in Britain. In the EAGLE-2 and EAGLE-3 trials it was non-inferior to nitrofurantoin for urinary infections and superior in EAGLE-3, while in the EAGLE-1 trial it matched ceftriaxone plus azithromycin for gonorrhoea. The most common side effects were diarrhoea, nausea and stomach pain.
What the Evidence Shows
New antibiotics are desperately needed because resistance is rising. A landmark study estimated that drug-resistant bacterial infections directly caused 1.27 million deaths worldwide in 2019, and gonorrhoea in particular is becoming harder to treat as strains resist more drugs. Gepotidacin works through a mechanism distinct from existing antibiotic classes, which is why it can kill bacteria that resist older drugs. But it is expensive and carries warnings, including a risk of heart rhythm changes and Clostridioides difficile infection, so experts say it should be reserved for patients without other options. Guidelines still recommend nitrofurantoin, trimethoprim-sulfamethoxazole or fosfomycin as first-line treatment for urinary infections. Careful stewardship will decide whether the new drug stays useful or follows older antibiotics into resistance. The drug is taken as tablets twice a day for five days for urinary infections, and doctors must weigh its benefits against the warnings on the label. Reporting and analysis from sources such as World Health Organization track the same developments, and specialists following gepotidacin, the new antibiotic say the direction is now consistent across independent lines of evidence.
The Wider Context
The wider context is a health system trying to move from treating illness late to preventing it early, against budgets that reward the opposite. Evidence around gepotidacin, the new antibiotic is being weighed by guideline committees that ask two questions in order: does it work, and can ordinary services actually deliver it at scale. Many good ideas pass the first test and stall on the second.
What Happens Next
What happens next for gepotidacin, the new antibiotic depends on the slow machinery of guidelines, funding and training catching up with the evidence. Patients asking about it today should expect honest answers that include uncertainty, and clinicians say a service that explains what is not yet known earns more trust than one that oversells. The research pipeline, at least, is moving in the right direction. You can follow related developments in our coverage of health.
There is a practical lesson in all of this for readers deciding what to do today. Start with the verified facts, be wary of anyone promising certainty, and prefer reversible steps while the evidence is still developing. Circumstances differ by country, income and personal situation, so general guidance should always be weighed against your own context before you act on it in any significant or lasting way.

